# Clinical Trial Related Articles

The Founder of Coinbase Is Going to Research Immortality

Coinbase founder Brian Armstrong has co-founded NewLimit, a longevity biotech startup, which just raised $435 million in a Series C funding round led by Peter Thiel’s Founders Fund. The round values the company at $3.1 billion, more than triple its valuation from a year ago. NewLimit is developing drugs aimed at reversing cellular aging to extend human healthspan. Its approach builds on Nobel Prize-winning research on cellular reprogramming (Yamanaka factors), with a focus on identifying specific gene combinations that can restore younger cell function. The company plans to begin human clinical trials next year, initially targeting alcohol-related liver disease as a form of accelerated aging. Founded in 2021 by Armstrong alongside biotech investor Blake Byers and scientist Jacob Kimmel, NewLimit has now raised over $700 million across multiple rounds. It joins a growing field of well-funded longevity ventures backed by tech billionaires, including Sam Altman’s Retro Biosciences and Jeff Bezos-backed Altos Labs, reflecting a surge of interest in using science to combat aging and extend healthy lifespan.

marsbit15h ago